Biopharmaceutical Startup’s Need of a Regulatory Strategy
DOI:
https://doi.org/10.5912/jcb675Keywords:
drug development, regulatory, approval, venture capital, investor, startupAbstract
Human drug development and approval is a risky process. To assess the importance of the regulatory part, especially for startup’s or not yet established companies, we gathered some evidence by a survey amongst European venture capital investors. We asked: how do regulatory issues in biopharmaceutical development impact young companies’ development and their financing? In addition to the survey an intensive literature research and analysis on drug failures and refusals was undertaken. Overall the expectations of involved venture capital investors identified were very congruent to the regulators views.
The most striking insight was that developing companies looking for first and follow on financing rounds should prepare to have a regulatory strategy or plan available already during the first contact. Regulatory issues are an important part of the risk/value evaluation and therefore investment decision.References
Jarvis, L.M. (2014) Help For Boys With Duchenne Muscular Dystrophy. Chem. Eng. News 92(29): 17–20. http://cen.acs.org/articles/92/i29/Help-Boys-Duchenne-Muscular-Distrophy.html, accessed 13 August2014.
Sacks, L.V et al. (2014) Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA: the journal of the American Medical Association 311(4): 378–384.
Wang, B., Avorn, J. and Kesselheim, A. (2013) Clinical and regulatory features of drugs not initially approved by the FDA. Clin. Pharmacol. Ther. 94(6): 670–677.
Tafuri, G., Trotta, F., Leufkens, H.G.M. and Pani, L. (2012). Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency. Br. J. Clin. Pharmacol. 75(4): 1149–1151.
Regnstrom, J. et al. (2009) Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66(1): 39–48.
Eichler, H.-G., Aronsson, B., Abadie, E. and Salmonson, T. (2010) New drug approval success rate in Europe in 2009. Nat. Rev. Drug Discov. 9(8): 355–356.
Schneider, C.K. and Schäffner-Dallmann, G. (2008) Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat. Rev. Drug Discov. 7(11): 893–899.
Ringel, M., Tollman, P., Hersch, G. and Schulze, U. (2013) Does size matter in R&D productivity? If not, what does? Nat. Rev. Drug Discov. 12(12): 901–902.
Czerepak, E. and Ryser, S. (2008) Drug approvals and failures: implications for alliances. Nat. Rev. Drug Discov. 7(3): 197–198.
